Plasma-derived therapies are essential for treating a wide range of conditions, including immune deficiencies, bleeding ...
The U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance for Fresenius Kabi’s Adaptive Nomogram, an alternate algorithm that will be available in the Aurora Xi Plasmapheresis System ...
The Aurora Xi Plasmapheresis System now benefits from enhanced capabilities that allow plasma centers to improve collection efficiency and support a greater supply of plasma-derived therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results